Detection of somatic mutations in human leukocyte antigen (HLA) genes using whole-exome sequencing

Detection of somatic mutations in human leukocyte antigen (HLA) genes using whole-exome sequencing (WES) is hampered by the high polymorphism of the HLA loci, which prevents alignment of sequencing reads to the human reference genome. We describe a computational pipeline that enables accurate inference of germline alleles of class I HLA-A, B and C genes and subsequent detection of mutations in these genes using the inferred alleles as a reference. Analysis of WES data from 7,930 pairs of tumor and healthy tissue from the same patient revealed 298 nonsilent HLA mutations in tumors from 266 patients. These 298 mutations are enriched for likely functional mutations, including putative loss-of-function events. Recurrence of mutations suggested that these 'hotspot' sites were positively selected. Cancers with recurrent somatic HLA mutations were associated with upregulation of signatures of cytolytic activity characteristic of tumor infiltration by effector lymphocytes, supporting immune evasion by altered HLA function as a contributory mechanism in cancer.

[1]  A. Townsend,et al.  Antigen recognition by class I-restricted T lymphocytes. , 1989, Annual review of immunology.

[2]  P Parham,et al.  Structure, function, and diversity of class I major histocompatibility complex molecules. , 1990, Annual review of biochemistry.

[3]  P. Stastny,et al.  DNA typing for HLA class I alleles: I. Subsets of HLA-A2 and of -A28. , 1992, Human immunology.

[4]  J. Sidney,et al.  Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules , 1993, Cell.

[5]  D. Speiser,et al.  Oligotyping of HLA-A2, -A3, and -B44 subtypes. Detection of subtype incompatibilities between patients and their serologically matched unrelated bone marrow donors. , 1994, Human immunology.

[6]  N. Greenspan,et al.  Class I MHC alpha 3 domain can function as an independent structural unit to bind CD8 alpha. , 1995, Molecular immunology.

[7]  M. Bunce,et al.  Molecular typing for the MHC with PCR-SSP. , 1999, Reviews in immunogenetics.

[8]  Gen Tamiya,et al.  Complete sequence and gene map of a human major histocompatibility complex , 1999 .

[9]  Complete sequence and gene map of a human major histocompatibility complex. The MHC sequencing consortium. , 1999, Nature.

[10]  L. Fugger,et al.  Identification of 4 different alternatively spliced HLA-A transcripts. , 1999, Tissue antigens.

[11]  P. Stern,et al.  Multiple mechanisms underlie HLA dysregulation in cervical cancer. , 2000, Tissue antigens.

[12]  F. Garrido,et al.  A nucleotide insertion in exon 4 is responsible for the absence of expression of an HLA-A*0301 allele in a prostate carcinoma cell line , 2001, Immunogenetics.

[13]  Vladimir Brusic,et al.  Prediction of promiscuous peptides that bind HLA class I molecules , 2002, Immunology and cell biology.

[14]  D. Speiser,et al.  Alpha 3 domain mutants of peptide/MHC class I multimers allow the selective isolation of high avidity tumor-reactive CD8 T cells. , 2003, Journal of Immunology.

[15]  D. Speiser,et al.  α3 Domain Mutants of Peptide/MHC Class I Multimers Allow the Selective Isolation of High Avidity Tumor-Reactive CD8 T Cells1 , 2003, The Journal of Immunology.

[16]  J. Bubeník,et al.  MHC class I down-regulation: tumour escape from immune surveillance? (review). , 2004, International journal of oncology.

[17]  W. Zou.  Regulatory T cells, tumour immunity and immunotherapy , 2006, Nature Reviews Immunology.

[18]  James Robinson,et al.  The IMGT/HLA database , 2008, Nucleic Acids Res..

[19]  N. Lennon,et al.  Next-generation sequencing for HLA typing of class I loci , 2011, BMC Genomics.

[20]  Vladimir Brusic,et al.  Ultra-high resolution HLA genotyping and allele discovery by highly multiplexed cDNA amplicon pyrosequencing , 2012, BMC Genomics.

[21]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer , 2011, Nature Biotechnology.

[22]  A. Sivachenko,et al.  SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. , 2011, The New England journal of medicine.

[23]  R. Schreiber,et al.  Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.

[24]  A. McKenna,et al.  The Mutational Landscape of Head and Neck Squamous Cell Carcinoma , 2011, Science.

[25]  Andrew R. Jones,et al.  Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations , 2010, Nucleic Acids Res..

[26]  Richard A. Moore,et al.  Derivation of HLA types from shotgun sequence datasets , 2012, Genome Medicine.

[27]  J. Castle,et al.  HLA typing from RNA-Seq sequence reads , 2012, Genome Medicine.

[28]  Wendy S. W. Wong,et al.  Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs , 2012, Bioinform..

[29]  S. Krishnakumar,et al.  High-throughput, high-fidelity HLA genotyping with deep sequencing , 2012, Proceedings of the National Academy of Sciences.

[30]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of squamous cell lung cancers , 2012, Nature.

[31]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[32]  A. Sivachenko,et al.  A Landscape of Driver Mutations in Melanoma , 2012, Cell.

[33]  Eric S. Lander,et al.  Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing , 2012, Proceedings of the National Academy of Sciences.

[34]  Helene Polin,et al.  Rapid, scalable and highly automated HLA genotyping using next-generation sequencing: a transition from research to diagnostics , 2013, BMC Genomics.

[35]  Adam A. Margolin,et al.  Enabling transparent and collaborative computational analysis of 12 tumor types within The Cancer Genome Atlas , 2013, Nature Genetics.

[36]  J. Harrow,et al.  Systematic evaluation of spliced alignment programs for RNA-seq data , 2013, Nature Methods.

[37]  M. Zody,et al.  ATHLATES: accurate typing of human leukocyte antigen through exome sequencing , 2013, Nucleic acids research.

[38]  Mauricio O. Carneiro,et al.  The advantages of SMRT sequencing , 2013, Genome Biology.

[39]  H. Kim,et al.  HLA Haplotyping from RNA-seq Data Using Hierarchical Read Weighting , 2013, PloS one.

[40]  A. McKenna,et al.  Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia , 2012, Cell.

[41]  M. Ni,et al.  Inference of high resolution HLA types using genome-wide RNA or DNA sequencing reads , 2014, BMC Genomics.

[42]  A. Sivachenko,et al.  Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.

[43]  Xun Xu,et al.  An Integrated Tool to Study MHC Region: Accurate SNV Detection and HLA Genes Typing in Human MHC Region Using Targeted High-Throughput Sequencing , 2013, PloS one.

[44]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of gastric adenocarcinoma , 2014, Nature.

[45]  Benjamin Schubert,et al.  OptiType: precision HLA typing from next-generation sequencing data , 2014, Bioinform..

[46]  M. Irimia,et al.  Origin of spliceosomal introns and alternative splicing. , 2014, Cold Spring Harbor perspectives in biology.

[47]  Scott D. Brown,et al.  Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival , 2014, Genome research.

[48]  S. Gabriel,et al.  Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.

[49]  Eric S. Lander,et al.  A polygenic burden of rare disruptive mutations in schizophrenia , 2014, Nature.

[50]  N. Hacohen,et al.  Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity , 2015, Cell.